Iovance Biotherapeutics Inc
(HAM:2LB)
€
3.775
+0.090 (+2.44%)
Market Cap: 1.64 Bil
Enterprise Value: 1.41 Bil
PE Ratio: 0
PB Ratio: 2.54
GF Score: 44/100 Iovance Biotherapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days Transcript
Feb 11, 2021 / 05:00PM GMT
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
Okay. Hello. I'm Michael Schmidt, Senior Biotech Analyst with Guggenheim Securities, and it's my pleasure to welcome Maria Fardis, who is the CEO of Iovance Therapeutics (sic) [Iovance Biotherapeutics]. Maria, welcome, and thanks for joining us.
Maria Fardis
Iovance Biotherapeutics, Inc. - CEO, President & Director
Thank you so much for having us.
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
Great. So before we go through Q&A, would you like to give a quick overview for those who are less familiar with the company?
Maria Fardis
Iovance Biotherapeutics, Inc. - CEO, President & Director
Yes, absolutely. So Iovance Biotherapeutics is a company that is developing cell therapy -- autologous cell therapy for patients with solid tumors. We are developing tumor-infiltrating lymphocytes or TIL technology for
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot